Description:

Size: 100ul

Catalog no.: bs-6809R-A594

Price: 380 EUR

Product details

Gene ID Number

9166

Modification Site

None

Target Antigen

RCAS1

Tested applications

IF(IHC-P)

French translation

anticorps

Modification

Unmodified

Clonality

Polyclonal

Excitation emission

590nm/617nm

Concentration

1ug per 1ul

Subcellular location

Extracellular

Crossreactivity

Human, Mouse, Rat

Conjugated with

ALEXA FLUOR® 594

Conjugated

Alexa conjugate 1

Recommended dilutions

IF(IHC-P)(1:50-200)

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Category

Conjugated Primary Antibodies

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Also known as

Anti-RCAS1 PAb ALEXA FLUOR 594

Host Organism

Rabbit (Oryctolagus cuniculus)

Specificity

This is a highly specific antibody against RCAS1.

Long name

RCAS1 Polyclonal Antibody, ALEXA FLUOR 594 Conjugated

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human RCAS1

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Synonyms

BAG9; Cancer associated surface antigen; Cancer associated surface antigen RCAS1; EB9; EBAG 9; Estrogen receptor binding fragment associated gene 9 protein; Estrogen receptor binding site associated antigen 9; PDAF; RCAS 1; RCAS1; Receptor binding cancer antigen expressed on SiSo cells.

Background of the antigen

EBAG9 is a type III transmembrane protein that is predominantly located in the Golgi. It induces apoptosis of natural killer (NK)/T cells and plays a role in immune invasion, possibly in relation to Epstein-Bar virus infection. EBAG9 is abundantly expressed in prostate cancer cells when compared to normal epithelial cells, and immunodetection of EBAG9 expression can be a negative prognostic indicator for patients with prostate cancer.